In the present cohort of intermediate- and high-risk PC patients planned for RP, 15/406 (3.7%) patients had equivocal bone lesions on their preoperative PSMA-targeted PET/CT staging. The gene discussed is FOLH1; the disease is pachyonychia congenita.